SSP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SSP is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is still in a mixed-to-bearish technical setup, there is no fresh positive news catalyst, no strong proprietary buy signal, and the latest analyst target was cut even though the Buy rating was maintained. I would not call this a clear buy at the current price of $3.12.
The short-term momentum is improving but the broader trend remains weak. MACD histogram is positive and expanding, which suggests near-term upside momentum. RSI_6 at 65.1 is neutral to slightly strong, not oversold. However, the moving averages are bearish with SMA_200 > SMA_20 > SMA_5, which confirms the longer-term trend is still down. Price is sitting just below R1 at 3.157 with pivot support at 2.87, so the stock is trading near a short-term resistance area rather than a clean breakout zone.
Analyst firm Benchmark still keeps a Buy rating, which supports the idea that the market sees some longer-term value. The options market is skewed toward calls, suggesting some bullish positioning. MACD is improving, and the price is close to near-term resistance, so a breakout could attract interest if momentum continues.
No news in the recent week means there is no current event-driven catalyst. The latest analyst action cut the price target from $10 to $8, which is still bullish but clearly less confident than before. Technical trend remains bearish on the longer horizon. Hedge funds and insiders are neutral, with no meaningful buying support. There is no recent congress trading data or notable political/influential figure activity.
Financial snapshot data was not available due to an error, so there is no latest quarter financial readout to assess. Because the latest quarter season is unavailable, I cannot confirm recent revenue, EBITDA, or margin growth trends from the provided data.
Recent analyst trend is still positive on rating but weaker on price target: Benchmark lowered its target to $8 from $10 while keeping a Buy rating. That suggests the Wall Street view is constructive but less aggressive on upside than before. Pros: differentiated business narrative, continued Buy rating. Cons: reduced target, large-scale M&A uncertainty until Washington clarity improves, and high-profile antitrust issues are still a concern. Overall, pros are present but the target cut signals moderation in conviction.
